- Home
- A-Z Publications
- Current Pharmaceutical Biotechnology
- Previous Issues
- Volume 14, Issue 12, 2013
Current Pharmaceutical Biotechnology - Volume 14, Issue 12, 2013
Volume 14, Issue 12, 2013
-
-
Luteolin Inhibits Smooth Muscle Cell Migration and Proliferation by Attenuating the Production of Nox4, P-Akt and VEGF in Endothelial Cells
Authors: Hong Ding, Dongye Li, Yanbin Zhang, Tian Zhang, Hong Zhu, Tongda Xu, Yuanyuan Luo and Cheng WangObjective: The goals of this study were to observe how luteolin protects endothelial cells (ECs) from injury stimulated by Angiotensin II (Ang II), investigate the role of vascular endothelial dysfunction in vascular smooth muscle cell proliferation and migration in vitro and investigate its primary mechanism of action. Methods: A non-contact coculture system was established using a transwell system; ECs were cultured in Read More
-
-
-
Pharmaceutical Applications of Graphene-based Nanosheets
Authors: Mi-Gyeong Kim, Joo Y. Park, Yuna Shon, Gayong Shim and Yu-Kyoung OhGraphene-based nanosheets (GNS) are atomic-thickness monolayers of hexagonally arranged, graphite-derived carbon atoms that may be composed of graphene, graphene oxide, or reduced graphene oxide. They have attracted tremendous interest for their potential in pharmaceutical applications, due to their unique physical, chemical, and mechanical properties GNS exhibit highly uniform surface areas and may have Read More
-
-
-
Pterostilbene as a Potential Novel Telomerase Inhibitor: Molecular Docking Studies and Its in vitro Evaluation
Pterostilbene is a naturally occurring dimethyl ether analog of resveratrol identified in several plant species. Telomerase is important in tumor initiation and cellular immortalization. Given the striking correlations between telomerase activity and proliferation capacity in tumor cells, telomerase had been considered as a potentially important molecular target in cancer therapeutics. Molecular docking studies were per Read More
-
-
-
Development and Characterization of a Gel Formulation Integrating Microencapsulated Nitrofurazone
Nitrofurazone (NTZ) is usually employed in the topical treatment of infected wounds and lesions of both skin and mucosa. Microencapsulation is a process utilized in the incorporation of active ingredients within polymers aiming at, among other objectives, the prolonged release of pharmaceutical compounds and protection from atmospheric agents (viz. moisture, light, heat and/or oxidation). With the goal of utilizin Read More
-
-
-
Construction of an Anti-IL-1β scfv and TNFRI Fusion Protein and Its Therapeutic Effect on RA Mice Model
Authors: Fangming Kan, Guiping Ren, Mo Guo, Jianying Qi, Yu Zhang, Yang Han, Yakun Zhang and Deshan LiIL-1β and TNF-α play key roles in the inflammatory response. Their abnormal expression may cause the occurrence of various diseases, such as RA. Recently, medicines of target TNF-α and IL-1β have become popular in the clinical practice. Although these biological agents can get mostly good results, they are not effective in all patients. The reason for this result may be that these biological agents could not fully inhibit a variety Read More
-
-
-
In vivo behavior and Safety of Lapatinib-Incorporated Lipid Nanoparticles
Authors: Huile Gao, Chen Chen, Zhangjie Xi, Jun Chen, Qizhi Zhang, Shilei Cao and Xinguo JiangTo improve the solubility, bioavailability and anti-tumor effect of lapatinib, lapatinib-incorporated lipid nanoparticles (LTNPs) were prepared and characterized. The particle size of LTNPs was 88.6 nm with a zeta potential of 20 mV. Laptinib was loaded into LTNPs with a non-crystal structure as determined by FT-IR. In vitro, LTNPs could be effectively uptaken into C6 glioma cells at a concentration-dependent manner. In vivo, LTN Read More
-
-
-
Developing Immunologically Inert Adeno-Associated Virus (AAV) Vectors for Gene Therapy: Possibilities and Limitations
Authors: Ruchita S. Selot, Sangeetha Hareendran and Giridhara R. JayandharanGene therapy has become a clinical reality as demonstrated by remarkable benefits seen in Phase I/II clinical trials for hemophilia B, lipoprotein lipase deficiency and Leber’s congenital amarousis. The choice of, and the improved understanding in vector characteristics have contributed significantly to this success. The adeno-associated virus (AAV) vectors used in these trials have been long known to be relatively safe an Read More
-
Volumes & issues
-
Volume 26 (2025)
-
Volume 25 (2024)
-
Volume 24 (2023)
-
Volume 23 (2022)
-
Volume 22 (2021)
-
Volume 21 (2020)
-
Volume 20 (2019)
-
Volume 19 (2018)
-
Volume 18 (2017)
-
Volume 17 (2016)
-
Volume 16 (2015)
-
Volume 15 (2014)
-
Volume 14 (2013)
-
Volume 13 (2012)
-
Volume 12 (2011)
-
Volume 11 (2010)
-
Volume 10 (2009)
-
Volume 9 (2008)
-
Volume 8 (2007)
-
Volume 7 (2006)
-
Volume 6 (2005)
-
Volume 5 (2004)
-
Volume 4 (2003)
-
Volume 3 (2002)
-
Volume 2 (2001)
-
Volume 1 (2000)
Most Read This Month
Article
content/journals/cpb
Journal
10
5
false
en
